NCT03939377

Brief Summary

The culture of the palliative is anchored more and more in France. In 2009, nearly 9 out of 10 French people (89%) believe that palliative care can reduce the suffering of people at the end of their lives. Despite the rise of palliative care in France, their access is not homogeneous between regions. In 2010, it is estimated that 2 French out of 3 likely to receive palliative care could not access it. Palliative care remains essential at the end of the patient's life, as well as for the family and caregivers. The French government has put in place three national palliative care development programs: 2002-2005, 2008-2012, 2015-2018. The last program has unlocked a budget of 190 million euros for their development. It has been estimated from Social Security reimbursements, that the costs per patient over their last years of life are 26,000 euros, for a total of 13.5 million euros. One of the most important aspects of palliative care is the comfort of the patients as well as their feelings in the care. In order to best meet the expectations of cancer patients, some offer early palliative care that is effective in improving both the quality of life of the patient and its life expectancy. Osteopathy is a manual alternative medicine whose goal is to restore the lack of mobility of tissues. It can be used as a complementary treatment when a specific support is put in place. The purpose of this study is to examine the effectiveness of osteopathy in the reduction of pain in adult patients in palliative care.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for not_applicable pain

Timeline
Completed

Started Mar 2019

Typical duration for not_applicable pain

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2019

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

May 3, 2019

Completed
3 days until next milestone

First Posted

Study publicly available on registry

May 6, 2019

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2021

Completed
Last Updated

June 23, 2021

Status Verified

June 1, 2021

Enrollment Period

2.2 years

First QC Date

May 3, 2019

Last Update Submit

June 22, 2021

Conditions

Keywords

PalliativeOsteopathy

Outcome Measures

Primary Outcomes (1)

  • VAS (Visual Analog Scale) evaluation (0 to 100)

    Evolution of the score of the Visual Analogue Scale (VAAS) on 100 between D0 and D6 and D0 and D1, D0 and D2, D0 and D3, D0 and D4, D0 and D5

    day 6

Secondary Outcomes (2)

  • Dose of analgesic (g)

    day 6

  • QLQ (Quality of life questionnaire) C15 Pal score

    days 6

Study Arms (2)

Osteopathy

EXPERIMENTAL

Management will be centered on the skull, the sacrum, the cranio-sacral axis, the entire visceral abdominal and thoracic system.

Other: Questionnaire and treatment

Simulate

PLACEBO COMPARATOR

The simulated treatment will be characterized by placing the practitioner's hands on the patient in the areas tested without any intention of treatment.

Other: Questionnaire and treatment

Interventions

EVA questionnaire every day for 7 days. treatment (real or simulated) at J3 and J5

OsteopathySimulate

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Major patient (age\> 18) male or female
  • Patient hospitalized or admitted to a day hospital that can be followed
  • EVA between 40/100 and 60/100
  • Signed informed consent

You may not qualify if:

  • Patients requiring a modification of analgesic molecule during the study.
  • Clinical stability of the patient estimated during the duration of the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHI Creteil

Créteil, 94000, France

Location

MeSH Terms

Conditions

Pain

Interventions

Surveys and QuestionnairesTherapeutics

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Data CollectionEpidemiologic MethodsInvestigative TechniquesHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public Health

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 3, 2019

First Posted

May 6, 2019

Study Start

March 1, 2019

Primary Completion

May 1, 2021

Study Completion

May 1, 2021

Last Updated

June 23, 2021

Record last verified: 2021-06

Data Sharing

IPD Sharing
Will not share

Locations